Mortality associated with long-term opioid use after lung cancer surgery: an infographic
Eric S. Schwenka b c✉, Rajnish K. Guptab d e
- aDepartment of Anesthesiology, Sidney Kimmel Medical College at Thomas Jefferson University, Philadelphia, Pennsylvania, USA
- bDepartment of Anesthesiology
- cSidney Kimmel Medical College at Thomas Jefferson University
- dDepartment of Anesthesiology, Vanderbilt University Medical Center, Nashville, Tennessee, USA
- eVanderbilt University Medical Center
- ✉Corresponding author
Papers open inside SciRah from the original publisher or repository; SciRah never hosts them.
Abstract
SUMMARY In a large retrospective cohort study using the South Korean National Health Insur-ance Database, Oh and colleagues 1 found that previously opioid- naïve patients who were still taking opioids 6 months postoper-atively after lung cancer surgery had a 40% (HR=1.40; 95% CI 1.29 to 1.52; p<0.001) greater risk of 2- year all- cause mortality. The authors divided patients into potent and less potent opioid users based on the specific drugs they were taking at 6 months, with codeine, dihydrocodeine, and tramadol being less potent opioids and fentanyl, morphine, oxycodone, hydromorphone, and metha-done being potent opioids. Users of potent opioids had a 92% (HR=1.92; 95% CI 1.67 to 2.21; p<0.001) greater risk of 2- year all-cause mortality, while users of less potent opioids had a 22% (HR=1.22; 95% CI 1.10 to 1.36; p<0.001) greater risk. Character-istics associated with new long- term opioid use included older age, male sex, wider surgical extent, open thoracotomy, increased Charlson Comorbidity Index score, neoadju-vant or adjuvant chemotherapy, preoperative anxiety disorder, and insomnia disorder.
TL;DRCharacter-istics associated with new long- term opioid use included older age, male sex, wider surgical extent, open thoracotomy, increased Charlson Comorbidity Index score, neoadju-vant or adjuvant chemotherapy, preoperative anxiety disorder, and insomnia disorder. (Semantic Scholar)